In a separate analysis of patients with 1 of 10 prespecified advanced rare tumor types previously conducted through the Aarhus University pathology network, the prevalence of PD-L1 positivity varied from 13% in patients with neuroendocrine tumors (n=30) to 86% in patients with vulvar carcinoma (n=44) (26). This evidence concerns the gene CD274 and neuroendocrine neoplasm.